我国药品不良反应损害救济风险分担机制研究  

Study on Adverse Drug Reaction Damage Relief Risk Sharing Mechanism in China

作　　者：王华[1] 杨悦[1] 

机构地区：[1]沈阳药科大学工商管理学院,辽宁沈阳110016

出　　处：《中国药物警戒》2010年第2期100-102,共3页Chinese Journal of Pharmacovigilance

摘　　要：目的探索完善我国药品不良反应损害救济风险分担机制的方法。方法采用文献研究方法、比较研究方法,描述我国现行法律关于药品不良反应损害赔偿的问题,通过借鉴国外和我国台湾地区药品不良反应损害救济制度,提出完善我国药品不良反应损害救济风险分担机制的建议。结果与结论侵权责任方面,我国产品缺陷界定存在不足,应加以完善;专门救济方面,我国应通过药品不良反应损害责任保险和药品不良反应损害救济基金分担药品不良反应损害风险。Objective To explore the ways to consummate the adverse drug reaction（ADR） damage relief risk sharing mechanism in our country. Methods Using literature and comparative method, we analyzed the present situation of the current legal regulations on ADR damage relief and put forward some suggestions on the improvement of the existing ADR damage relief risk sharing mechanism by referring to ADR damage relief system of Taiwan and foreign countries. Results ＆ Conclusion Our existing tort liability has problem in product flaw limits and we should consummate through this aspect. We should also share ADR damage risks through ADR liability insurance and ADR damage relief foundation from the ADR special relief aspect.

关 键 词：药品不良反应 侵权责任 专门救济 

分 类 号：R954[医药卫生—药学]